BNP Paribas Financial Markets Sells 300,559 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

BNP Paribas Financial Markets cut its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 60.5% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 196,225 shares of the biotechnology company's stock after selling 300,559 shares during the period. BNP Paribas Financial Markets owned approximately 0.09% of BioCryst Pharmaceuticals worth $1,476,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Venturi Wealth Management LLC acquired a new position in BioCryst Pharmaceuticals during the 4th quarter worth approximately $46,000. R Squared Ltd acquired a new position in BioCryst Pharmaceuticals during the 4th quarter worth approximately $48,000. KBC Group NV increased its holdings in BioCryst Pharmaceuticals by 80.1% during the 4th quarter. KBC Group NV now owns 10,198 shares of the biotechnology company's stock worth $77,000 after purchasing an additional 4,537 shares in the last quarter. Raymond James Financial Inc. bought a new stake in BioCryst Pharmaceuticals during the 4th quarter worth approximately $80,000. Finally, Syon Capital LLC bought a new stake in BioCryst Pharmaceuticals during the 4th quarter worth approximately $99,000. 85.88% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have commented on BCRX shares. Wedbush started coverage on BioCryst Pharmaceuticals in a report on Tuesday, February 25th. They set an "outperform" rating and a $15.00 price objective for the company. Royal Bank of Canada reissued an "outperform" rating and set a $13.00 price objective (up from $11.00) on shares of BioCryst Pharmaceuticals in a report on Tuesday, May 6th. JMP Securities reissued a "market outperform" rating and set a $18.00 price objective on shares of BioCryst Pharmaceuticals in a report on Friday, January 31st. Wall Street Zen raised BioCryst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Thursday. Finally, HC Wainwright reissued a "buy" rating and set a $30.00 price objective on shares of BioCryst Pharmaceuticals in a report on Tuesday, May 6th. One equities research analyst has rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Buy" and an average price target of $16.56.

BioCryst Pharmaceuticals Stock Up 1.9%

BioCryst Pharmaceuticals stock traded up $0.20 during trading on Friday, hitting $10.59. The stock had a trading volume of 3,608,168 shares, compared to its average volume of 3,026,377. BioCryst Pharmaceuticals, Inc. has a 1 year low of $5.92 and a 1 year high of $11.11. The stock's 50 day moving average is $8.38 and its two-hundred day moving average is $8.05. The stock has a market cap of $2.22 billion, a price-to-earnings ratio of -17.36 and a beta of 1.08.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last posted its quarterly earnings data on Monday, February 24th. The biotechnology company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.06). The company had revenue of $131.50 million during the quarter, compared to analyst estimates of $126.64 million. The company's revenue was up 40.8% compared to the same quarter last year. During the same quarter last year, the firm posted $0.28 EPS. As a group, equities research analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current fiscal year.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.